Viridian Therapeutics
VRDN
8 hedge funds and large institutions have $341K invested in Viridian Therapeutics in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
13% more capital invested
Capital invested by funds: $303K → $341K (+$38K)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
11% less funds holding
Funds holding: 9 → 8 (-1)
Top Buyers
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$29.4K |
| 2 |
Renaissance Technologies
New York
|
+$11.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$112 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
HighTower Advisors
Chicago,
Illinois
| $235K | +$29.4K | +264 | +14% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $50K | – | – | – |
|
|
PCM
3
Perkins Capital Management
Wayzata,
Minnesota
| $25K | -$10.7K | -96 | -31% |
|
|
4
Renaissance Technologies
New York
| $19K | +$11.2K | +100 | +147% |
|
5
Citadel Advisors
Miami,
Florida
| $5K | -$12.3K | -110 | -71% |
|
6
Creative Planning
Overland Park,
Kansas
| $5K | -$1.67K | -15 | -25% |
|
|
BFA
7
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$112 | +1 | +17% |
|
|
8
UBS Group
Zurich,
Switzerland
| $1K | +$1K | +9 | New |
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$11K | -120 | Closed |
|
VRDN Hedge Fund Activity: Q3 2016 in Review
8 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2016, worth a combined $341K — up 13% from $303K a quarter earlier.
Fund positioning in VRDN was balanced in Q3 2016: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was HighTower Advisors, adding an estimated $29.4K. The largest seller was Citadel Advisors, cutting an estimated $12.3K.
- 8 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2016, down from 9 in Q2 2016.
- Funds reported $341K of Viridian Therapeutics stock for Q3 2016, up 13% quarter-over-quarter.
- 1 fund opened new Viridian Therapeutics positions in Q3 2016 and 1 closed out, a net change of 0 holders.
- The largest Viridian Therapeutics buyer in Q3 2016 was HighTower Advisors, an estimated $29.4K added.
- The largest Viridian Therapeutics seller in Q3 2016 was Citadel Advisors, an estimated $12.3K sold.
Based on aggregated 13F filings for Q3 2016.